MULTIPLE MYELOMA IN RELAPSE
Clinical trials for MULTIPLE MYELOMA IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA IN RELAPSE trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail targets Hard-to-Treat myeloma
Disease control OngoingThis study tests a combination of four drugs (daratumumab, carfilzomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients achieve tumor shrinkage and how long the benefit …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Andrew Yee, MD • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot aims to wipe out myeloma in patients out of options
Disease control OngoingThis phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Quick-Made cancer fighter put on hold: new CAR-T study withdrawn
Disease control TerminatedThis study aimed to test a new type of CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that had returned or stopped responding to treatment. The therapy was made from a simple blood draw and took less time to produce than standard CAR-T cells. However, the…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to control hard-to-treat myeloma
Disease control OngoingThis study tests three different drug combinations containing selinexor (Xpovio) for people whose multiple myeloma has returned or stopped responding to treatment. About 18 adults will receive a combination chosen by their doctor. The goal is to see how well these treatments shri…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Three-Drug cocktail aims to tame relapsed myeloma
Disease control OngoingThis study tests a combination of three oral drugs—ixazomib, pomalidomide, and dexamethasone—given twice weekly to people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe and effective dose that controls the cancer. The tri…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail aims to keep relapsed myeloma in check
Disease control OngoingThis phase II study tests whether a combination of elotuzumab, pomalidomide, and dexamethasone can help control relapsed multiple myeloma after a second stem cell transplant. The trial enrolls 25 adults whose myeloma returned after their first transplant. Participants receive the…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for Tough-to-Treat myeloma: early safety trial of HPN217 begins
Disease control OngoingThis study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves through the bo…
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Online tool aims to empower myeloma patients
Knowledge-focused OngoingThis study tests whether a health technology platform called All4Cure can help people with multiple myeloma become more active in managing their own health. Two hundred participants will fill out surveys about their symptoms and how confident they feel in handling their care. No …
Matched conditions: MULTIPLE MYELOMA IN RELAPSE
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:51 UTC